Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Lung Cancer | Research

Regulation of cancer stem cells by CXCL1, a chemokine whose secretion is controlled by MCM2

Authors: Yeon-Jee Kahm, In-Gyu Kim, Rae-Kwon Kim

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

A high expression pattern of minichromosome maintenance 2 (MCM2) has been observed in various cancers. MCM2 is a protein involved in the cell cycle and plays a role in cancer growth and differentiation by binding to six members of the MCM subfamily. The MCM protein family includes MCM2 through MCM7.

Methods

MCM2 has shown high expression in both lung cancer stem cells (LCSCs) and glioma stem cells (GSCs). We investigated the characteristics of CSCs and the regulation of the epithelial-to-mesenchymal transition (EMT) phenomenon in LCSCs and GSCs by MCM2. Additionally, we explored secreted factors regulated by MCM2.

Results

There was a significant difference in survival rates between lung cancer patients and brain cancer patients based on MCM2 expression. MCM2 was found to regulate both markers and regulatory proteins in LCSCs. Moreover, MCM2 is thought to be involved in cancer metastasis by regulating cell migration and invasion, not limited to lung cancer but also identified in glioma. Among chemokines, chemokine (C-X-C motif) ligand 1 (CXCL1) was found to be regulated by MCM2.

Conclusions

MCM2 not only participates in the cell cycle but also affects cancer cell growth by regulating the external microenvironment to create a favorable environment for cells. MCM2 is highly expressed in malignant carcinomas, including CSCs, and contributes to the malignancy of various cancers. Therefore, MCM2 may represent a crucial target for cancer therapeutics.
Appendix
Available only for authorised users
Literature
1.
Zhai Y, Li N, Jiang H, Huang X, Gao N, Tye BK. Unique roles of the non-identical MCM subunits in DNA replication licensing. Mol Cell. 2017;67:168–79.CrossRefPubMed
2.
3.
Tye BK. The MCM2-3-5 proteins: are they replication licensing factors? Trends Cell Biol. 1994;4(5):160–6.CrossRefPubMed
4.
Nishitani H, Lygerou Z. Control of DNA replication licensing in a cell cycle. Genes Cells. 2002;7(6):523–34.CrossRefPubMed
5.
Evrin C, Clarke P, Zech J, Lurz R, Sun J, Uhle S, Li H, Stillman B, Speck C. A double-hexameric MCM2-7 complex is loaded onto origin DNA during licensing of eukaryotic DNA replication. Proc Natl Acad Sci U S A. 2009;106(48):20240–5.ADSPubMedCentralCrossRefPubMed
6.
Remus D, Beuron F, Tolun G, Griffith JD, Morris EP, Diffley JF. Concerted loading of Mcm2-7 double hexamers around DNA during DNA replication origin licensing. Cell. 2009;139(4):719–30.PubMedCentralCrossRefPubMed
7.
Sun J, Evrin C, Samel SA, Fernández-Cid A, Riera A, Kawakami H, Stillman B, Speck C, Li H. Cryo-EM structure of a helicase loading intermediate containing ORC-Cdc6-Cdt1-MCM2-7 bound to DNA. Nat Struct Mol Biol. 2013;20(8):944–51.PubMedCentralCrossRefPubMed
8.
9.
Liao X, Liu X, Yang C, Wang X, Yu T, Han C, Huang K, Zhu G, Su H, Qin W, Huang R, Yu L, Deng J, Zeng X, Ye X, Peng T. Distinct diagnostic and prognostic values of Minichromosome Maintenance Gene Expression in patients with Hepatocellular Carcinoma. J Cancer. 2018;9(13):2357–73.PubMedCentralCrossRefPubMed
10.
Datta A, Ghatak D, Das S, Banerjee T, Paul A, Butti R, Gorain M, Ghuwalewala S, Roychowdhury A, Alam SK, Das P, Chatterjee R, Dasgupta M, Panda CK, Kundu GC, Roychoudhury S. p53 gain-of‐function mutations increase Cdc7‐dependent replication initiation. EMBO Rep. 2017;18(11):2030–50.PubMedCentralCrossRefPubMed
11.
Milanovic M, Fan DNY, Belenki D, Däbritz JHM, Zhao Z, Yu Y, Dörr JR, Dimitrova L, Lenze D, Monteiro Barbosa IA, Mendoza-Parra MA, Kanashova T, Metzner M, Pardon K, Reimann M, Trumpp A, Dörken B, Zuber J, Gronemeyer H, Hummel M, Dittmar G, Lee S, Schmitt CA. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553(7686):96–100.ADSCrossRefPubMed
12.
13.
Chang JC. Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance. Med (Baltim). 2016;95(1 Suppl 1):S20–5.ADSCrossRef
14.
Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol. 2011;223(2):147–61.CrossRefPubMed
15.
Shibata M, Hoque MO. Targeting Cancer Stem cells: a strategy for effective eradication of Cancer. Cancers (Basel). 2019;11(5):732.CrossRefPubMed
16.
17.
18.
Senese S, Lo YC, Huang D, Zangle TA, Gholkar AA, Robert L, Homet B, Ribas A, Summers MK, Teitell MA, Damoiseaux R, Torres JZ. Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development. Cell Death Dis. 2014;5(10):e1462.PubMedCentralCrossRefPubMed
19.
20.
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, Cui H. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.PubMedCentralCrossRefPubMed
21.
22.
Albini A, Bruno A, Gallo C, Pajardi G, Noonan DM, Dallaglio K. Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res. 2015;56(5):414–25.PubMedCentralCrossRefPubMed
23.
24.
Korkaya H, Liu S, Wicha MS. Regulation of Cancer Stem cells by Cytokine networks: attacking cancers inflammatory roots. Clin Cancer Res. 2011;17(19):6125–9.PubMedCentralCrossRefPubMed
25.
Kartikasari AER, Huertas CS, Mitchell A, Plebanski M. Tumor-Induced Inflammatory cytokines and the Emerging Diagnostic devices for Cancer Detection and Prognosis. Front Oncol. 2021;11:692142.PubMedCentralCrossRefPubMed
26.
Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, Levine H, Onuchic JN, Jolly MK. Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proc Natl Acad Sci U S A. 2019;116(1):148–57.ADSCrossRefPubMed
27.
López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol. 2020;13(1):136.PubMedCentralCrossRefPubMed
28.
Girbl T, Lenn T, Perez L, Rolas L, Barkaway A, Thiriot A, Del Fresno C, Lynam E, Hub E, Thelen M, Graham G, Alon R, Sancho D, von Andrian UH, Voisin MB, Rot A, Nourshargh S. Distinct compartmentalization of the chemokines CXCL1 and CXCL2 and the atypical receptor ACKR1 determine Discrete stages of Neutrophil Diapedesis. Immunity. 2018;49(6):1062–e10766.PubMedCentralCrossRefPubMed
29.
Sawant KV, Xu R, Cox R, Hawkins H, Sbrana E, Kolli D, Garofalo RP, Rajarathnam K. Chemokine CXCL1-Mediated neutrophil trafficking in the lung: role of CXCR2 activation. J Innate Immun. 2015;7(6):647–58.PubMedCentralCrossRefPubMed
30.
Ravindran A, Sawant KV, Sarmiento J, Navarro J, Rajarathnam K. Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor. J Biol Chem. 2013;288(17):12244–52.PubMedCentralCrossRefPubMed
31.
Baston-Büst DM, Schanz A, Böddeker SJ, Altergot-Ahmad O, Krüssel JS, Rein D, Hess AP. CXCL1 expression in human decidua in vitro is mediated via the MAPK signalling cascade. Cytokine. 2013;64(1):79–85.CrossRefPubMed
32.
Wei ZW, Xia GK, Wu Y, Chen W, Xiang Z, Schwarz RE, Brekken RA, Awasthi N, He YL, Zhang CH. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Lett. 2015;359(2):335–43.CrossRefPubMed
33.
Wang Y, Liu J, Jiang Q, Deng J, Xu F, Chen X, Cheng F, Zhang Y, Yao Y, Xia Z, Xu X, Su X, Huang M, Dai L, Yang Y, Zhang S, Yu D, Zhao RC, Wei Y, Deng H. Human adipose-derived mesenchymal stem cell-secreted CXCL1 and CXCL8 facilitate breast Tumor Growth by promoting angiogenesis. Stem Cells. 2017;35(9):2060–70.CrossRefPubMed
34.
Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203(4):941–51.PubMedCentralCrossRefPubMed
35.
Lo HM, Shieh JM, Chen CL, Tsou CJ, Wu WB. Vascular endothelial growth factor induces CXCL1 chemokine release via JNK and PI-3K-Dependent pathways in human lung carcinoma epithelial cells. Int J Mol Sci. 2013;14(5):10090–106.PubMedCentralCrossRefPubMed
36.
Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massagué J. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165–78.PubMedCentralCrossRefPubMed
37.
Xu J, Zhang C, He Y, Wu H, Wang Z, Song W, Li W, He W, Cai S, Zhan W. Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer. 2012;130(4):787–97.CrossRefPubMed
38.
Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol. 2011;22(10):2267–76.CrossRefPubMed
39.
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL. Aldehyde dehydrogenase 1 is a Tumor Stem Cell-Associated marker in Lung Cancer. Mol Cancer Res. 2009;7(3):330–8.PubMedCentralCrossRefPubMed
40.
Choi SI, Lee JH, Kim RK, Jung U, Kahm YJ, Cho EW, Kim IG. HSPA1L enhances Cancer Stem Cell-Like Properties by activating IGF1Rβ and regulating β-Catenin transcription. Int J Mol Sci. 2020;21(18):6957.PubMedCentralCrossRefPubMed
41.
Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, Price ND, Hood LE, Tian Q. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A. 2011;108(4):1591–6.ADSPubMedCentralCrossRefPubMed
42.
Clément C, Almouzni G. MCM2 binding to histones H3–H4 and ASF1 supports a tetramer-to-dimer model for histone inheritance at the replication fork. Nat Struct Mol Biol. 2015;22(8):587–9.CrossRefPubMed
43.
44.
Abe S, Yamamoto K, Kurata M, Abe-Suzuki S, Horii R, Akiyama F, Kitagawa M. Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. Oncotarget. 2015;6(33):34892–909.PubMedCentralCrossRefPubMed
45.
Zhou X, Luo J, Xie H, Wei Z, Li T, Liu J, Liao X, Zhu G, Peng T. MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling. Cell Death Discov. 2022;8(1):418.PubMedCentralCrossRefPubMed
Metadata
Title
Regulation of cancer stem cells by CXCL1, a chemokine whose secretion is controlled by MCM2
Authors
Yeon-Jee Kahm
In-Gyu Kim
Rae-Kwon Kim
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12085-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

m1A regulator-mediated methylation modification patterns correlated with autophagy to predict the prognosis of hepatocellular carcinoma

Research

Demographic and clinical characteristics associated with advanced stage colorectal cancer: a registry-based cohort study in Saudi Arabia

Research

Correlation between spleen density and prognostic outcomes in patients with colorectal cancer after curative resection

Research

EMP3 as a prognostic biomarker correlates with EMT in GBM

Research

Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma

Research

Effects of a ‘Rebuilding Myself’ intervention on enhancing the adaptability of cancer patients to return to work: a randomized controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits